Prevalence of anemia in clinic patients with heart failure and cost analysis of epoetin treatment

Pharmacotherapy

Volumn 27, Issue 5, 2007, Pages 707-714

  Choy, Christine K ^a,b   Spencer, Anne P ^a   Nappi, Jean M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Anemia; Economic decision analysis; Epoetin; Erythropoietin; Heart failure

Indexed keywords

IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; COST BENEFIT ANALYSIS; DRUG COST; FEMALE; HEART FAILURE; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NORMOCHROMIC NORMOCYTIC ANEMIA; PREVALENCE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; ANEMIA; CARDIAC OUTPUT, LOW; CHRONIC DISEASE; COHORT STUDIES; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; EPOETIN ALFA; FEMALE; HEALTH CARE COSTS; HEMATINICS; HOSPITALIZATION; HUMANS; IRON; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 34247874533     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.5.707     Document Type: Article

References (38)

1. Mansen TJ, McCance KL. Alterations of erythrocyte function. In: McCance KL, Huether SE, eds. Pathophysiology: the biologic basis for disease in adults and children. St. Louis, MO: Mosby, 2002:843-64.
2. Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in older persons. JAMA 1999;281:1714-7.
3. Anonymous. IV. NKF-K/DOQI clinical practice guidelines for. anemia of chronic kidney disease: update 2000. Am J Kid Dis 2001;37(suppl 1):S182-237.
4. (Erratum in Am J Kid Dis 2001;38(2):442.)
5. National Center for Health Statistics, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Anemia/iron deficiency. Available from www.cdc.gov/nchs/fastats/anemia.htm. Accessed June 4, 2006.
6. Kosiborod M, Curtis JP, Want Y, et al. Anemia and outcomes in patients with heart failure. Arch Intern Med 2005;165:2237-44.
7. Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005;112:1121-7.
8. Das SR, Dries DL, Drazner MH, Yancy CW, Chae CU. Relation of lower hematocrit to progression from asymptomatic left ventricular dysfunction to symptomatic heart failure (from the studies of left ventricular dysfunction prevention trial). Am J Cardiol 2005;96:827-31.
9. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity, and significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39:1780-6.
10. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes. Circulation 2003;107:223-5.
11. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). Circulation 2005;112:154-235. Available from http://circ.ahajournals.org/cgi/reprint/112/12/ e154. Accessed April 15, 2006.
12. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 2005;149:391-401.
13. Androne AS, Katz SD, Lund L, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003;107:226-9.
14. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST). Circulation 2001;103:2055-9.
15. Macdougall IC, Copper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002;17(suppl 11):39-43.
16. Jensen JD, Eiskjaer H, Bagger JP, Pedersen EB. Elevated level of erythropoietin in congestive heart failure: relationship to renal perfusion and plasma renin. J Intern Med 1993;233:125-30.
17. Volpe M, Tritto C, Testa U, et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical hemodynamic and hormonal profiles. Am J Cardiol 1994;74:468-73.
18. Pham I, Andrivet P, Sediame S, et al. Increased erythropoietin synthesis in patients with COLD or left heart failure is related to alterations in renal haemodynamics. Eur J Clin Invest 2001;31:103-9.
19. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001:37:1775-80.
20. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107:294-9.
21. Silverberg SD, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737-44.
22. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-6.
23. Silverberg DS, Wexler D, Blum M, et al. Effects of treatment with epoetin beta on outcomes in patient with anaemia and chronic heart failure. Kidney Blood Press Res 2005;28:41-7.
24. Fonarow GC. The acute decompensated heart failure national registry (ADHERE): opportunities to improve care of patients with-acute decompensated heart failure. Rev Cardiovasc Med 2003;4(suppl 7):S21-30.
25. Watson Pharma, Inc. Infed (iron dextran injection, USP) package insert. Morristown, NJ; 2001.
26. American Regent, Inc. Venofer (iron sucrose injection, USP) package insert. Shirley, NJ; 2005.
27. Watson Pharma, Inc. Ferrlecit (sodium ferric gluconate complex in sucrose injection) package insert. Corona, CA; 2004.
28. Clarke JL, Nash DB. The effectiveness of heart failure disease management: initial findings from a comprehensive program. Dis Manage 2002;4:215-23.
29. Bennett SJ, Saywell RM, Zollinger TW, Huster GA, Ford EC, Pressler ML. Cost of hospitalization for heart failure: sodium retention versus other decompensating factors. Heart Lung 1999;28:102-9.
30. U.S. Department of Labor, Bureau of Labor Statistics. Consumer price indexes. Available from www.bls.gov/cpi. Accessed April 15, 2006.
31. Fleming T, ed. Drug topics red book. Montvale, NJ: Thompson PDR, 2005.
32. General Clinical Research Center, Medical University of South Carolina, Charleston, SC. Clinical trials center: nursing services. Available from www.ctc.musc.edu/nursing.html. Accessed April 14, 2006.
33. General Clinical Research Center at the Arizona Health Sciences Center. Fee schedule. Available from www.gcrc.arizona.edu/fee-schedule.htm. Accessed April 15, 2006.
34. General Clinical Research Center at the University of Pittsburgh. Industry rates MUH-CTRC. Available from www.gcrc.pitt.edu/content.asp?id=1467. Accessed April 15, 2006.
35. American Heart Association, American Stroke Association. Heart disease and stroke statistics: 2006 update. At-a-glance. Available from www.americanheart.org/downloadable/heart/ 113535864858055-1026_HS_Stats06book. pdf. Accessed June 27, 2006.
36. Cleland JG, Coletta AP, Clark AL, Velavan P, Ingle L. Clinical trials update from the European Society of Cardiology heart failure meeting and the American College of Cardiology: darbepoetin alpha study, ECHOS, and ASCOT-BPLA. Eur J Heart Fail 2005;7:937-9.
37. Coletta AP, Tin L, Loh PH, Clark AL, Cleland JG. Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902. Eur J Heart Fail 2006;8:547-9.
38. Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney disease and risks of death and hospitalization in adults with chronic heart failure. Circulation 2006;113:2713-23.